Дозированный ингалятор или небулайзер:научные доказательства и реальная практика

1. Dolovich MJ, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005; 127: 335–71.
2. Brocklebank D, Ram F, Wright J et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5 (26): 1–139.
3. Ploin D, Chapuis FR, Stamm D et al. High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: a double-blind, randomized equivalence trial. Pediatrics 2000; 106: 311–7.
4. Dahl R, Greefhorst LA, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–84.
5. Sutherland ER, Brazinsky S, Feldman G. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI. Curr Med Res Opin 2009; 25 (3): 653–61.
6. Авдеев С.Н., Суточникова О.А., Белевский А.С., Чучалин А.Г. Небулизированный будесонид (суспензия Пульмикорта) при тяжелом обострении ХОБЛ. Пульмонология. 2003; 5: 81–8.
7. Nicolini G, Cremonesi G, Melani AS. Inhaled corticosteroid therapy with nebulized beclometasone dipropionate. Pulm Pharmacol Ther 2009.
8. Manthous CA, Hall JB, Schmidt GA et al Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients. Am Rev Respir Dis 1993; 148: 1567–70.
9. Donohue JF, Hanania NA, Fogarty C et al. Long term safety of nebulised formoterol: Results of a Twelve-month Open-label clinical trial. Ther Adv Resp Dis 2008; 2 (4): 199–208.
10. www.piluli.ru.
11. Clark N, Houle C, Partridge M et al. The puzzle of continued use of nebulized therapy by those with asthma. Chronic Respirat Dis 2010; 7 (1): 3–7.
12. Mason N, Roberts N, Yard N, Partridge M. Nebulizers or spacers for the administration of bronchodilators to those with asthma attending emergency departments. Respir Med 2008; 102: 993–8.
13. Paterson IC, Crompton GK. Use of pressurised aerosols by asthmatic patients. BMJ 1976; 1: 76–7.
14. Cochrane MG, Bala MV, Downs KE et al Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–50.
15. Melani AS, Zanchetta D, Barbato N. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol 2004; 93: 439–46.
16. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005; 50: 1360–74.
17. Osmond M, Diner B. Evidence-based emergency medicine. Nebulizers versus inhalers with spacers for acute asthma in pediatrics. Annal Emer Med 2004; 43: 413–5.
18. Tien I, Dorfman D, Kastner B, Bauchner H. Metereddoseinhaler: the emergency department orphan. Arch Pediatr Adolesc Med 2001; 155: 1335–9.
19. Canny GJ, Levison H. Aerosols-therapeutic use and delivery in childhood asthma. Ann Allergy 1988; 60: 11–9.
20. Pierce RJ, McDonald CF, Landau LI et al. Nebuhaler versuswet aerosol for domiciliary bronchodilator therapy (Adults). Med J Aust 1992; 156: 771–4.
21. Татарский А.Р., Бобков Е.В., Бабак С.Л. Роль небулайзеров в терапевтической практике. Cons. Med. 2007; 9 (3).
22. Wright J, Brocklebank D, Ram F. Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD). Qual Saf Health Care 2002; 11: 376–82.
23. Goodman DE, Israel E, Rosenberg M et al The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Car Med 1994; 150: 1256–61.
24. Kamin W, Schwabe A, Kramer I. Inhalation solutions -which ones are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulisers. J Cyst Fibros 2006; 5: 205–13.
25. Rau JL. Determinants of Patient Adherence to an Aerosol Regimen Respir Car 2005; 50 (10): 1346–56.

А.В.Аверьянов